175 related articles for article (PubMed ID: 35538247)
1. Optic pathway glioma and endocrine disorders in patients with and without NF1.
Gil Margolis M; Yackobovitz-Gavan M; Toledano H; Tenenbaum A; Cohen R; Phillip M; Shalitin S
Pediatr Res; 2023 Jan; 93(1):233-241. PubMed ID: 35538247
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment Endocrine Disorders Due to Optic Pathway Gliomas in Pediatric Neurofibromatosis Type 1: Multicenter Study.
Santoro C; Perrotta S; Picariello S; Scilipoti M; Cirillo M; Quaglietta L; Cinalli G; Cioffi D; Di Iorgi N; Maghnie M; Gallizia A; Parpagnoli M; Messa F; De Sanctis L; Vannelli S; Marzuillo P; Miraglia Del Giudice E; Grandone A
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32294191
[TBL] [Abstract][Full Text] [Related]
3. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
4. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
5. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
[TBL] [Abstract][Full Text] [Related]
6. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
7. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
Florent C; Beylerian M; Mairot K; Dambricourt L; André N; David T; Girard N; Audic F; Denis D
J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579
[TBL] [Abstract][Full Text] [Related]
9. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
[TBL] [Abstract][Full Text] [Related]
10. Natural history and outcome of optic pathway gliomas in children.
Nicolin G; Parkin P; Mabbott D; Hargrave D; Bartels U; Tabori U; Rutka J; Buncic JR; Bouffet E
Pediatr Blood Cancer; 2009 Dec; 53(7):1231-7. PubMed ID: 19621457
[TBL] [Abstract][Full Text] [Related]
11. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.
Chang L; El-Dairi MA; Frempong TA; Burner EL; Bhatti MT; Young TL; Leigh F
J AAPOS; 2010 Dec; 14(6):511-7. PubMed ID: 21168074
[TBL] [Abstract][Full Text] [Related]
12. Endocrine Long-Term Follow-Up of Children with Neurofibromatosis Type 1 and Optic Pathway Glioma
.
Sani I; Albanese A
Horm Res Paediatr; 2017; 87(3):179-188. PubMed ID: 28346917
[TBL] [Abstract][Full Text] [Related]
13. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
15. Optic Gliomas in Neurofibromatosis Type 1.
Parkhurst E; Abboy S
J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):334-338. PubMed ID: 27537249
[TBL] [Abstract][Full Text] [Related]
16. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ
Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
[TBL] [Abstract][Full Text] [Related]
17. Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
Sharafi P; Varan A; Ersoy-Evans S; Ayter S
Childs Nerv Syst; 2024 Feb; 40(2):511-515. PubMed ID: 37401974
[TBL] [Abstract][Full Text] [Related]
18. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.
Sellmer L; Farschtschi S; Marangoni M; Heran MKS; Birch P; Wenzel R; Mautner VF; Friedman JM
Orphanet J Rare Dis; 2018 Apr; 13(1):62. PubMed ID: 29685181
[TBL] [Abstract][Full Text] [Related]
19. Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications.
Shamji MF; Benoit BG
Neurosurg Focus; 2007; 23(5):E3. PubMed ID: 18004965
[TBL] [Abstract][Full Text] [Related]
20. The role of surgery in optic pathway/hypothalamic gliomas in children.
Goodden J; Pizer B; Pettorini B; Williams D; Blair J; Didi M; Thorp N; Mallucci C
J Neurosurg Pediatr; 2014 Jan; 13(1):1-12. PubMed ID: 24138145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
